International Reference Pricing – Healthcare Economist

Reference pricing in the US for COVID drugs?

2023-09-15Jason Shafrin

Perhaps according to a report from Stat News: A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.The contract between Regeneron and the government requires…

International Reference Pricing: List vs. Net Pricing issues

2021-04-23Jason ShafrinLeave a comment

Leah Rand and Aaron Kesselheim have an interesting commentary in Value in Health reviewing some of the challenges of implementing international reference pricing (IRP) in the U.S. IRP would set drug prices in the U.S. as no higher than a basket of drug prices in other developed countries. This issue is of particular interest due…